Most MSL teams are measured on activity. Visits, calls, decks delivered. Oncologists evaluate them on something else entirely. New ZoomRx research surfaces the gap between dashboard metrics and what physicians actually report, and points at what to measure instead.
Insights in this article are drawn from the ZoomRx Oncology Medical Engagement Perception Report 2026, a perception study of 51 US oncology specialists who had interacted with at least one MSL team in the prior three months.
For most oncology Medical Affairs teams, the gap between what the internal dashboard says and what oncologists actually report is wide enough to invalidate the dashboard. The question is no longer whether to acknowledge the gap. It is what to use instead.
The awkward truth about most medical science liaison (MSL) KPIs is that they measure presence, not impact.
A visit is recorded whether the conversation moved the HCPs or did not. A slide deck is logged whether it was useful or forgotten by the end of the day. A follow-up is captured whether it answered the original question or restated what was already said. Activity counts go up. Whether anything changed is left to assumption.
Years ago, when MSL teams were smaller and oncology was simpler, activity counts were a reasonable proxy for impact. They are not anymore. The HCP population is finite. Every interaction either earns a relationship or quietly costs one. Counting them tells you almost nothing about which.
When ZoomRx asked 51 oncology specialists what they got out of their MSL interactions, the picture was clearer than most dashboards make it look. The top three outcomes:
A second tier of outcomes, clinical decision refinement, congress and advisory board engagement, confidence improvement, sat between 29 and 35 percent.
And at the bottom of the list: internal field team connectivity, at 18 percent. The lowest outcome in the study. Internal connectivity is a legitimate part of the MSL role, but it is also the one outcome that mostly serves the manufacturer, not the physician. That is a useful gut check on where most MSL teams are spending their effort, and where oncologists say the value is actually being created.
“Activity belongs in operational dashboards. Impact belongs in leadership reviews. Most companies are putting both into the same green light and losing visibility into where their team is actually creating value.”
The measurement system that would actually work has a specific shape. It measures what oncologists value, not just what the MSL did. It tracks knowledge closure, research activation, and peer influence, the outcomes oncologists themselves credit MSLs with. It separates operational metrics (activity, internal connectivity) from leadership metrics (impact, perception, competitive position). And it runs continuously against the competitor set, not as a one-time audit.
This is ZoomRx's Medical Engagement Effectiveness Tracker (MET). MET is ZoomRx's HCP-direct field measurement system. It surfaces physician-reported outcomes on your MSL team, runs continuously against your competitor set, and gives Medical Affairs leadership a clear view of where the team is actually creating value and where it is not. The dashboard you build internally measures what your team did. MET measures what your physicians actually got out of it.
The right question is not, are our MSL numbers good. The numbers will almost always look fine. The right question is:
If we asked the oncologists in our highest-priority accounts to rate our MSL team across the attributes they care about, would the answer match what our dashboard is telling us?
For most companies, the honest answer is we do not know. That is not a failure. It is an opportunity. The data is now collectible. The decision is whether to collect it.
If your internal dashboard and your oncologists' experience tell two different stories, the dashboard isn't wrong it's incomplete. Get in Touch with us to see what your activity view can't show you physician-reported outcomes on knowledge closure, research activation, and peer influence and to explore a zero-cost MET pilot tailored to your field team.